AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
BSF Enterprise PLC (LSE:BSFA), a biotech company listed on the Main Market and owner of Kerato Ltd, has announced a research partnership with the University of Montreal in Canada. This agreement outlines the terms for a collaborative effort aimed at advancing a new treatment for corneal damage.
Kerato Ltd, a wholly-owned subsidiary of BSF, specializes in commercializing innovations in tissue engineering with a focus on corneal applications. The company is dedicated to developing new treatments for corneal damage through both in vitro and in vivo approaches.
Collaborative Research Focus
The partnership between Kerato Ltd and the University of Montreal will leverage the expertise of both parties to advance the development of an in-situ gelling cornea. This novel approach is intended to address corneal damage and full-thickness perforations. The collaboration aims to combine tissue engineering knowledge to improve treatment options.
Corneal Transplantation and Market Context
Corneal transplants are the most common type of human tissue transplant, with approximately 185,000 procedures performed annually. However, around 55% of the global population lacks access to donor corneas, leaving about 12.7 million people in need of transplants. The artificial cornea and corneal implant market was valued at $421 million in 2021, with Kerato estimating its target market at $37.6 million. This market is projected to grow at an annual rate of 6.9%, reaching $767.5 million by 2030.
Innovative Treatment Approach
Kerato’s new treatment involves combining host corneal stromal cells with a synthetic extracellular matrix protein to aid tissue healing and surface re-epithelialization. The treatment is administered through injections, offering a less invasive alternative to full transplant surgeries. This method is anticipated to simplify procedures, reduce hospital stays, lower the risk of graft rejection, cut costs for healthcare providers, and improve patient outcomes.
Tissue Regeneration and Intellectual Property
The resulting tissue from Kerato's treatment uses the patient's own stromal cells, which are transparent and replicate the natural curvature of the eye. Stromal cells contribute to the extracellular matrix, which supports organ structure. Previous research by Kerato’s academic partners has highlighted the importance of corneal stromal cells in creating a healthy extracellular matrix and the role of biomechanics in tissue regeneration.
Progression Through Clinical Trials
The collaboration with the University of Montreal aims to build on previous pre-clinical studies led by Professor May Griffith. The project will move forward with safety and efficacy testing, clinical trials, and regulatory approvals before introducing the treatment to global markets.
Veterinary Trial Plans
To mitigate risks and expedite market entry, the new treatment will first be tested in veterinary settings. This approach will provide broader access to complex corneal repair treatments for animals.
Future Development and Goals
Kerato Ltd is focused on advancing its tissue engineering and bio-engineered corneal products. The company is developing two key applications: an Implantable Medical Device and an Ocular Toxicity Testing Platform. Sarah Greenhalgh, Managing Director of Kerato Ltd, expressed enthusiasm about the partnership, noting its potential to transform corneal regenerative therapies and improve both cost-efficiency and patient outcomes.
